is tirzepatide a diabetic drug Eli Lilly's weight loss, diabetes tops Keytruda as world's best-selling medicine Weight Loss/Diabetic Drug Tirzepatide Slashes

The National Institute for Health and Care Excellence (NICE) has not issued guidance on GLP-1 receptor agonists for addiction treatment, and these medications should not be considered established therapies for substance use disorders

The active ingredient is bremelanotide acetate, while the inactive ones are 2.5% glycerin, sterile water for injection, and hydrochloric acid or sodium hydroxide added to adjust the pH

Zhang W, Wang T, Xue, et al

1 2 "Establishing the President's Make America Healthy Again Commission"

Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,748 followers

With your formula I take 3 or 4 injections a week 32 gauge with 5/16 needle in my belly and dont even feel them